91 results on '"Kapiteijn, E."'
Search Results
2. Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
3. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort
4. Health-state utilities in long-term advanced melanoma survivors comparable with the general population
5. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial
6. A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
7. CT radiomics to predict checkpoint inhibitors treatment outcomes in patients with advanced cutaneous melanoma
8. 31P The IOpener study: Tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer
9. 849P Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma
10. 791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
11. 859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma
12. 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)
13. 812P Early experiences in adjuvant treatment of melanoma: Real-world data on tolerability, safety and efficacy
14. 860P The IOpener study: Tyrosine kinase activity in peripheral lymphocytes to predict durable response to immune checkpoint inhibition in patients with advanced melanoma
15. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
16. Endocriene tumoren
17. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
18. P71 The Development of a Flexible and Easy to Tailor Disease Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma by Combining Trial and Real-World Data
19. POSC365 Health State Utilities of Advanced Melanoma Patients Treated in Clinical Practice in the Era of Novel Immuno- and Targeted Therapies
20. POSB361 Quality of Life in Advanced Melanoma Patients in the Era of Novel Immuno- and Targeted Therapies
21. POSC366 Validity of the EQ-5D-3L and EQ-5D-5L in Advanced Melanoma
22. 23P A comprehensive analysis of the mucosal melanoma immune microenvironment
23. Time trends in treatment strategies and survival of older versus younger patients with synchronous metastasized melanoma – a population-based study in the Netherlands Cancer Registry
24. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
25. Survival of stage IV melanoma in Belgium and the Netherlands
26. 1499P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab: Week 60 update of the PRADO trial
27. 1018P Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
28. 1750P Molecular genotyping in refractory thyroid cancers: Results of a European survey
29. 1081P Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
30. 1070P Adjuvant treatment for melanoma in clinical practice: Trial versus reality
31. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
32. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry
33. 37P First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis
34. Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls
35. 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition
36. 1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial
37. 1120P Post-approval trials versus patient registries: Comparability of advanced melanoma patients with brain metastases
38. 1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
39. 1103P Long-term survival of real-world advanced melanoma patients treated with targeted therapy
40. 1200P Tyrosine kinase activity profiling as a predictive biomarker for clinical benefit to immune checkpoint inhibition in advanced melanoma and NSCLC
41. 1130P BRAF and MEK inhibition in CDKN2A germline carriers and BRAF mutant melanoma
42. Treatment strategies and overall survival for incurable metastatic colorectal cancer – A EURECCA international comparison including 21,196 patients from the Netherlands and Norway
43. Multicentre study of short-course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer
44. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data
45. PCN501 VALUE FOR MONEY IN METASTATIC CUTANEOUS MELANOMA: DO BENEFITS OUTWEIGH THE COSTS OF NOVEL DRUGS?
46. PCN497 A NATIONWIDE COST OF ILLNESS STUDY OF METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS
47. A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature
48. Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
49. ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
50. P2.04-06 Blood-Based Multiplex Kinase Activity Profiling as a Predictive Marker for Clinical Response to Checkpoint Blockade in Advanced NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.